赛沃替尼片 | China Drugs ListSavolitinib tablets | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 1. 用于携带间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。 2. 联合奥希替尼，用于EGFR基因突变阳性、经EGFR酪氨酸激酶抑制剂治疗后进展、伴MET扩增的局部晚期或转移性非鳞状非小细胞肺癌患者。 3. 用于经过至少2种系统治疗后失败、MET基因扩增的局部晚期或转移性胃癌或胃食管结合部腺癌成人患者；该胃癌适应症为附条件批准。1. Treatment of adults with locally advanced or metastatic NSCLC with MET exon 14 skipping. 2. With osimertinib for EGFR mutation-positive locally advanced or metastatic nonsquamous NSCLC with MET amplification after progression on EGFR TKI therapy. 3. Treatment of adults with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with MET amplification after failure of at least two systemic therapies; this gastric cancer indication has conditional approval.
- 适应症来源与口径
- 来源日期： 2026-07-02, 2025. 适应症转录自国家医保局公开的企业申报资料；不代表已核实完整的现行说明书。Source date(s): 2026-07-02, 2025. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
- 说明书信息局限
- 尚未取得可核实的完整药品说明书。现有批准记录或国家医保局申报资料支持所示适应症；最新完整范围尚待确认。A verifiable complete prescribing-information document has not yet been obtained. Available approval records or NHSA submissions support the indications shown; the latest full scope needs confirmation.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限携带间质-上皮转化因子(MET)外显子14跳变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。Limited to adults with locally advanced or metastatic NSCLC with MET exon 14 skipping.
- 医保期限
- 2026-01-01 至 2026-12-312026-01-01 to 2026-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.